Form 4: Akero Therapeutics Senior VP Sells Shares Post-Novo Merger

Akero Therapeutics Senior VP Patrick Lamy disposed of common stock, restricted stock units, and stock options following the company's acquisition by Novo Nordisk, receiving cash and contingent value rights.

Summary

• Patrick Lamy, Senior VP, Commercial Strategy of Akero Therapeutics, Inc. (AKRO), reported the disposal of common stock, restricted stock units (RSUs), and stock options.
• These transactions occurred on December 9, 2025, as a direct result of the merger of Akero Therapeutics with NN Invest Sub, Inc., a subsidiary of Novo Nordisk A/S.
• The merger, effective December 9, 2025, resulted in Akero Therapeutics becoming a wholly-owned subsidiary of Novo Nordisk.
• Each share of Akero common stock was converted into the right to receive $54.00 in cash (Closing Consideration) and one contractual contingent value right (CVR) for an additional $6.00 if a specified milestone is achieved.
• Company RSUs were deemed fully vested, cancelled, and converted into the same Merger Consideration.
• Company stock options were deemed fully vested, cancelled, and converted into a cash payment equal to the product of the excess of the $54.00 Closing Consideration over the option's exercise price, multiplied by the number of shares, plus one CVR per share.
• Lamy disposed of 3,059 shares of common stock and 26,832 restricted stock units.
• Lamy also disposed of stock options with exercise prices ranging from $19.87 to $44.37, totaling 212,764 underlying shares.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, resulting in a cash payout and potential CVR for equity holders, which is generally positive for the reporting person and former shareholders. The company is no longer independent, which could be seen as a neutral or slightly negative aspect for some, but the transaction itself is a positive liquidity event.

Positives

• Completion of the merger with Novo Nordisk A/S, providing a clear exit strategy for shareholders and equity holders.
• The reporting person received a significant cash payout for their equity holdings, including vested RSUs and options.
• Potential for an additional $6.00 per share via CVRs if a specified milestone is achieved.

Negatives

• Akero Therapeutics ceases to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Novo Nordisk.
• Former shareholders no longer participate in the future growth or decline of Akero Therapeutics' stock price beyond the CVR terms.

Risks

• The $6.00 per share contingent value right (CVR) is dependent on the achievement of a specified milestone, meaning the full $60.00 per share consideration is not guaranteed.

Future Outlook

Akero Therapeutics is now a wholly-owned subsidiary of Novo Nordisk A/S. The future financial performance and strategic direction will be integrated within Novo Nordisk. The realization of the $6.00 CVR payment depends on the achievement of a specific, undisclosed milestone.

Management Comments

• Patrick Lamy's role is Senior VP, Commercial Strategy.
• Securities were disposed of pursuant to the terms of the Agreement and Plan of Merger, effective as of December 9, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Novo.
• At the Effective Time, each share of common stock was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 and (ii) one contractual contingent value right representing the right to receive $6.00 in cash, if a specified milestone is achieved.

Industry Context

This transaction reflects the ongoing trend of consolidation within the biopharmaceutical industry, where larger companies acquire smaller, innovative firms to expand their pipelines and market presence. Novo Nordisk's acquisition of Akero Therapeutics, a company focused on metabolic diseases, aligns with strategic efforts to strengthen portfolios in high-growth therapeutic areas.

Comparison to Industry Standards

• This Form 4 filing, which reports an insider's post-merger equity disposition, does not contain the necessary details (such as the pre-merger valuation, market premium, or specific financial rationale for the acquisition) to conduct a detailed comparison to global industry benchmarks or specific comparable companies and projects.
• However, the inclusion of a Contingent Value Right (CVR) as part of the merger consideration is a common practice in biopharmaceutical acquisitions, particularly when the acquired company has pipeline assets with future clinical or regulatory milestones. This structure is often employed to align incentives and share risk between the acquirer and the target's shareholders, similar to structures observed in various biopharma M&A deals where milestone payments are tied to drug development progress.

Corporate Governance

Stakeholder Impact

• Shareholders: Former shareholders of Akero Therapeutics received $54.00 in cash per share and one CVR for a potential additional $6.00, providing a liquidity event.
• Employees (including reporting person): Equity holdings (RSUs, options) were converted into cash and CVRs, providing financial benefit. The company's operational structure and employment terms may change under Novo Nordisk's ownership.
• Company (Akero Therapeutics): Ceased to be an independent public entity, now operating as a subsidiary of Novo Nordisk A/S.

Next Steps

• Monitoring the achievement of the specified milestone for the $6.00 CVR payment.
• Akero Therapeutics will operate as a wholly-owned subsidiary of Novo Nordisk A/S.

Key Dates

Keywords

Akero Therapeutics, AKRO, Novo Nordisk, Merger, Acquisition, Form 4, Insider Transaction, Beneficial Ownership, Stock Options, Restricted Stock Units, CVR, Contingent Value Right, Biopharma, Pharmaceutical